URB597 (Synonyms: FAAH Inhibitor II, URB-597, URB 597, KDS-4103) |
|
Catalog No.GC15951
|
An inhibitor of FAAH
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 546141-08-6
Sample solution is provided at 25 µL, 10mM.
URB597, also known as KDS-4103, is a potent and selective inhibitor of fatty-acid amide hydrolase (FAAH), an enzyme catalyzing the intracellular hydrolysis of the endocannabinoid anandamide, with values of 50% inhibition concentration IC50 of 5 nM and 3 nM in rat brain membranes and human liver microsomes respectively. Study results have shown that, through intraperitoneal (i.p.) administration, URB597 potently inhibits FAAH in rat brain with a median inhibitory dose ID50 of 0.15 mh/kg. However, URB597 fails to show significant inhibition against a few other cannabinoid-related targets (such as cannabinoid receptors and anandamide transport) as well as a broad range of receptors, ion channels, transporters and enymes.
Reference
[1].Daniele Piomelli, Giorgio Tarzia, Andrea Duranti, Andrea Tontini, Marco Mor, Timothy R. Compton, Oliver Dasse, Edward P. Monaghan, Jeff A. Parrot and David Putman. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Review 2006; 12(1): 21-38
| Cell experiment [1]: | |
|
Cell lines |
Rat brain cortical neurons |
|
Preparation method |
The solubility of this compound in DMSO is > 16.9 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
10 nM |
|
Applications |
URB597 selectively inhibited the breakdown of [3H]anandamide without reducing its carrier-mediated uptake, which caused non-metabolized [3H]anandamide to accumulate in, and finally exit from the cortical neurons. The accumulated [3H]anandamide was released from the neurons back into the media via passive diffusion rather than reverse transport. |
| Animal experiment [1]: | |
|
Animal models |
Rats |
|
Dosage form |
0.3 mg/kg; i.p. |
|
Applications |
In rats, URB597 rapidly inhibited FAAH (< 15 mins) and its inhibitory effect could last for over 12 hrs. Meanwhile, the contents of anandamide and other fatty-acid ethanolamides were significantly elevated in brain. In addition, URB597 markedly enhanced the hypothermic response caused by a sub-threshold dose of anandamide (5 mg/kg; i.p.). However, when injected alone, URB597 showed no effect on body temperature. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Daniele Piomelli, Giorgio Tarzia, Andrea Duranti, Andrea Tontini, Marco Mor, Timothy R. Compton, Oliver Dasse, Edward P. Monaghan, Jeff A. Parrot and David Putman. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Review 2006; 12(1): 21-38. |
|
| Cas No. | 546141-08-6 | SDF | |
| Synonyms | FAAH Inhibitor II, URB-597, URB 597, KDS-4103 | ||
| Chemical Name | [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate | ||
| Canonical SMILES | C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N | ||
| Formula | C20H22N2O3 | M.Wt | 338.4 |
| Solubility | ≥ 16.9 mg/mL in DMSO, ≥ 4.55 mg/mL in EtOH with ultrasonic and warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9551 mL | 14.7754 mL | 29.5508 mL |
| 5 mM | 591 μL | 2.9551 mL | 5.9102 mL |
| 10 mM | 295.5 μL | 1.4775 mL | 2.9551 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















